Aspirin in PCI; Mavacamten in Nonobstructive Cardiomyopathy; Olezarsen and the Treatment of Hypertriglyceridemia
Eagle's Eye View: Your Weekly CV Update From ACC.org
Release Date: 09/17/2025
Eagle’s Eye View: Highlights from the 2025 AHA Scientific Sessions
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle highlights several important studies presented at the recent American Heart Association Scientific Sessions. The OCEAN Trial on antithrombotic and stroke prevention in patients with atrial fibrillation (AFib). He then explores VESALIUS-CV, a study on evolocumab versus placebo in patients with atherosclerosis or diabetes and without previous myocardial infarction (MI) or stroke. Finally, Dr. Eagle discusses the POLY-HF study on the use of a daily polypill that boosts heart function, improves quality of life, and cuts hospitalizations in underserved...
info_outline
Highlights From 2025 TCT Conference
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle highlights several trials recently presented at the TCT Conference in San Francisco. The SELUTION DeNovo trial found that use of the sirolimus-eluting balloons with bailout stenting only if necessary was noninferior to routine drug-eluting stent implantation in patients with de novo coronary artery disease. In the ANDES trial, results showed that the use of direct oral anticoagulants after left atrial appendage closure in patients...
info_outline
Aspirin, Anticoagulants, & Chronic Coronary Disease; Perioperative Blood Pressure Management; High-Dose Flu Vaccines & Hospitalizations
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at a study comparing the use of aspirin and oral anticoagulants versus anticoagulants alone in the treatment of chronic coronary disease (CCD). He then explores complications after noncardiac surgery and the efficacy of perioperative blood pressure management. Finally, Dr. Eagle discusses FLUNITY-HD, a study comparing high-dose flu vaccines to standard dose vaccines in reducing hospitalizations.
info_outline
Heart Disease Mortality in California; Pregnant Women and Cardiometabolic Comorbidities; CABG and New-Onset AFib
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the social drivers behind the rise in heart disease mortality in California. He then explores the prevalence of preexisting cardiometabolic comorbidities and cardiovascular disease among pregnant women. Finally, Dr. Eagle discusses a recent prospective cohort study of patients who undergo coronary artery bypass graft (CABG) and experience new-onset atrial fibrillation (AFib), and how the burden after surgery is very low, especially after 30 days.
info_outline
Evidence and Innovations Targeting Inflammation Post-AMI
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the potential value of sodium-glucose cotransporter 2 (SGLT2) agents after transcatheter aortic valve implantation (TAVI). He then explores a new randomized trial, HYPERION, focusing on the addition of sotatercept to lower the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses a state-of-the-art review centered around the use of an anti-inflammatory to lessen cardiovascular events and worse outcomes following acute myocardial infarction (AMI).
info_outline
A Look at ACC’s Scientific Statement on Inflammation and CVD
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at an ACC Scientific Statement highlighting inflammation and its role in cardiovascular disease (CVD). He then explores left atrial appendage occlusion (LAAO) in patients with prior intracranial hemorrhage or ischemic stroke. Finally, Dr. Eagle discusses the recently released NEWTON-CABG CardioLink-5 trial on the use of evolocumab in the reduction of saphenous vein graft (SVG) disease rates.
info_outline
Oral Semaglutide for Weight Loss; Anticoagulants for PAH; The ECDP on TR Evaluation and Management
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the value of oral semaglutide for weight loss. He then explores whether anticoagulants improve survival in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses the recent release of the ACC Expert Consensus Decision Pathway (ECDP) on tricuspid regurgitation (TR) evaluation and management.
info_outline
Nonatherothrombotic Myocardial Infarction and SCAD in Younger Patients; the Benefit of Intensive Blood Pressure Control; Clopidogrel vs. Aspirin for Prevention of CV Events
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the net benefit of intensive blood pressure control between fewer cardiovascular and more adverse events. He then explores non-atherothrombotic myocardial infarction events and spontaneous coronary artery dissection (SCAD) in younger patients – something more commonly found among young women than young men. Finally, Dr. Eagle discusses whether clopidogrel is superior to aspirin for the prevention of major adverse cardiovascular or cerebrovascular events in patients with coronary artery disease (CAD).
info_outline
Aspirin in PCI; Mavacamten in Nonobstructive Cardiomyopathy; Olezarsen and the Treatment of Hypertriglyceridemia
Eagle's Eye View: Your Weekly CV Update From ACC.org
Dr. Eagle continues in this week’s View to analyze some of the key clinical content presented at the ESC Congress recently held in Spain. Dr. Eagle examines the TARGET-FIRST trial in which P2Y12-inhibitor monotherapy was compared to dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). He then analyzes the results of the ODYSSEY-HCM trial which explored mavacamten versus placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the ESSENCE-TIMI 73b study that looked at...
info_outline
Aficamten vs. Metoprolol for HCM; Beta Blocks and Myocardial Infarction (MI); Reconditioned Pacemakers for Improving Global CV Health
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at major trials presented at the recent ESC Congress in Spain. First, he discusses the MAPLE-HCM trial that investigates aficamten versus metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). He then explores a set of important presentations on beta blocker therapy following myocardial infarction. Finally, Dr. Eagle talks about new research on the use of reconditioned pacemakers that shows promise for strengthening global cardiovascular health.
info_outlineDr. Eagle continues in this week’s View to analyze some of the key clinical content presented at the ESC Congress recently held in Spain. Dr. Eagle examines the TARGET-FIRST trial in which P2Y12-inhibitor monotherapy was compared to dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). He then analyzes the results of the ODYSSEY-HCM trial which explored mavacamten versus placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the ESSENCE-TIMI 73b study that looked at olezarsen and its potential for lowering triglycerides in moderate hypertriglyceridemia with elevated cardiovascular risk.